Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 1, 2001, Pages 81-86

  Möller, Ulrich ^a   Hari, Yvonne ^a   Berchtold, Emanuel ^a  

^a Spital Netz Bern   (Switzerland)

Author keywords

Antihistamine pre medication; Bee venom allergy; Immunotherapy; Terfenadine

Indexed keywords

ANTIHISTAMINIC AGENT; BEE VENOM; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; PLACEBO; TERFENADINE;

ALLERGIC REACTION; ARTICLE; BEE STING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035141765     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.111852     Document Type: Article

References (26)

1. Reduction of side effects of specific immunotherapy by premedication with antihistaminics and reduction of maximal dosage to 50.000 SQ-U/ml
2. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine
3. Antihistamine premedication in specific cluster immunotherapy: A double-blind, placebo-controlled study
4. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial
5. Effect of pretreatment with cetirizine on side effects from rush-immunotherapy with honey bee venom
6. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: A double-blind, placebo-controlled trial
7. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
8. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
9. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: Comparison of rush and conventional immunotherapy
10. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects
11. CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy
12. Histamine: An early messenger in inflammatory and immune reactions
13. Generation of antigen-specific suppressor cells during allergy desensitization
14. Histamine receptor expression on peripheral blood CD4+ lymphocytes is influenced by ultra-rash bee venom immunotherapy
15. Venom immunotherapy in Hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment
16. Position paper: Immunotherapy with Hymenoptera venoms
17. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety
18. The Hymenoptera venom study III: Safety of venom immunotherapy
19. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy
20. Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients
21. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients
22. Heterogeneous effects of histamine on proliferation of lung and blood derived T-cell clones from healthy and asthmatic persons
23. Specific inhibition of TH2-type cytokine production from human peripheral T cells by terfenadine in vitro
24. Involvement of protein kinase A in histamine-mediated inhibition of IL-2 mRNA expression in mouse splenocytes
25. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC. Early Treatment of the Atopic Child
26. Diagnosis and treatment of insect sensitivity